Concepedia

Stephen Poor

SP

17

Publications

499

Citations

13

H-Index

2004

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

University College London

University of Bonn

Roche (Switzerland)

Stephen Poor is an author at Novartis (United States) specializing in drug discovery, ophthalmology, and glaucoma.

ORCID

Top concepts

Publications per year

2004–2023

17

Publications

17

Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation

Stephen Poor, Yubin Qiu, Elizabeth Fassbender et al. · Investigative Ophthalmology & Visual Science · 2014 · 72 citations · Full text

Risk Segmentation Related to the Offering of a Consumer‐Directed Health Plan: A Case Study of Humana Inc.

Laura Tollen, Murray N. Ross, Stephen Poor · Health Services Research · 2004 · 66 citations · Full text

Long-acting protein drugs for the treatment of ocular diseases

Joy G. Ghosh, Andrew Nguyen, Chad E. Bigelow et al. · Nature Communications · 2017 · 54 citations · Full text

A proteogenomic signature of age-related macular degeneration in blood

Valur Emilsson, Elías F. Guðmundsson, Brynjolfur G. Jonsson et al. · Nature Communications · 2022 · 44 citations · Full text

The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration

Christopher M. Adams, Karen Anderson, Gerald D. Artman et al. · Journal of Medicinal Chemistry · 2018 · 36 citations · Full text

, , +17

Rows per page

1–5 of 17